Revista Espanola De Medicina Nuclear E Imagen Molecular最新文献

{"title":"Uso de propranolol en 18F-FDG-PET/TC para el diagnóstico diferencial de grasa parda en una paciente con antecedente de adenocarcinoma de cérvix uterino","authors":"A. Garcia Garcia , A.P. Caresia Aróztegui , S. Martínez Román","doi":"10.1016/j.remn.2024.500068","DOIUrl":"10.1016/j.remn.2024.500068","url":null,"abstract":"","PeriodicalId":48986,"journal":{"name":"Revista Espanola De Medicina Nuclear E Imagen Molecular","volume":"44 1","pages":"Article 500068"},"PeriodicalIF":1.6,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143095659","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Efecto antitumoral de la vertebroplastia en la metástasis vertebral basado en el análisis cuantitativo de la PET/TC con 18F-FDG","authors":"L. Bian , C. Yang , S.-w. Yin , C.-f. Ni","doi":"10.1016/j.remn.2024.500028","DOIUrl":"10.1016/j.remn.2024.500028","url":null,"abstract":"","PeriodicalId":48986,"journal":{"name":"Revista Espanola De Medicina Nuclear E Imagen Molecular","volume":"44 1","pages":"Article 500028"},"PeriodicalIF":1.6,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143095661","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Gammagrafía peritoneal y SPECT/CT en el diagnóstico de fugas en pacientes en diálisis peritoneal","authors":"D. Tercero Garrido ,&nbsp;M.V. Guiote Moreno ,&nbsp;C. Rodelo-Haad ,&nbsp;P.I. Contreras Puertas ,&nbsp;S. Soriano Cabrera ,&nbsp;M.D. Albalá González","doi":"10.1016/j.remn.2024.500067","DOIUrl":"10.1016/j.remn.2024.500067","url":null,"abstract":"<div><h3>Objective</h3><div>To assess the usefulness of peritoneal cavity scintigraphy and the contribution of SPECT/CT in patients on peritoneal dialysis with suspected leak.</div></div><div><h3>Methodology</h3><div>An observational case series study is carried out. It consists of a longitudinal, retrospective and descriptive study. 11 patients on peritoneal dialysis were studied and it was realiced a peritoneal cavity scintigraphy test and SPECT/CT to evaluate a peritoneal leak.</div></div><div><h3>Results</h3><div>In 54,5% of the patients, a positive study of peritoneal leak was obtained. The most frequent localitations were in the abdominal wall at the catheter entry level and the inguinal hernia. In the cases with sintomatology like pain and celullitis of the subcutaneous tract of the cateter the frequent of leak was 100%. There was a change in therapeutic management in patients with a positive study. There was not relevant changes in initial dialysis regimen in patients with a negative study. In this cases, except for one patient who required hemodialysis, all patients experienced clinical improvement.</div></div><div><h3>Conclusions</h3><div>Peritoneal scintigraphy and SPECT/CT study are non-invasive techniques that allow an adequate diagnosis and subsequent management of peritoneal leak.</div></div>","PeriodicalId":48986,"journal":{"name":"Revista Espanola De Medicina Nuclear E Imagen Molecular","volume":"44 1","pages":"Article 500067"},"PeriodicalIF":1.6,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143135593","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Papel y aplicaciones de la 18F-FDG PET/TC en la evaluación de la infección e inflamación osteoarticular - Parte I","authors":"E. Noriega-Álvarez ,&nbsp;B. Rodríguez Alfonso ,&nbsp;J.J. Rosales Castillo ,&nbsp;A. Moreno Ballesteros ,&nbsp;E. López Rodríguez ,&nbsp;S. Sanz Viedma ,&nbsp;M. del P. Orduña Diez ,&nbsp;L. Domínguez Gadea","doi":"10.1016/j.remn.2024.500073","DOIUrl":"10.1016/j.remn.2024.500073","url":null,"abstract":"<div><div>¹⁸F-FDG PET/CT has been positioned over time as a useful tool in the evaluation of osteoarticular infections, overcoming conventional explorations like MRI or bone scintigraphy in some indications. Its ability to provide functional and anatomical images simultaneously and its excellent resolution contributes to a more precise and personalised approach in the treatment of osteoarticular diseases such as spondylodiscitis. In addition, it has proven valuable in patients with suspected infection that is complex to diagnose or treat, improving detection in subclinical stages. However, some limitations have been identified, such as difficulty in the differential diagnosis of infection vs. inflammation (as in diabetic foot) or in the interpretation of patients with osteosynthesis materials. In this manuscript, we present a brief review providing general and practical information about the role of ¹⁸F-FDG PET/CT in infectious osteoarticular pathology, while part 2 discusses the role of ¹⁸F-FDG PET/CT in osteoarticular inflammation.</div></div>","PeriodicalId":48986,"journal":{"name":"Revista Espanola De Medicina Nuclear E Imagen Molecular","volume":"44 1","pages":"Article 500073"},"PeriodicalIF":1.6,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143096746","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Respuesta, complicaciones y riesgo de transformación leucémica del tratamiento con fósforo-32 en los síndromes mieloproliferativos crónicos Philadelphia negativos","authors":"I. Tobalina Larrea ,&nbsp;J. Cuetos Fernández ,&nbsp;A. Mendizabal Abad ,&nbsp;A. Montero de la Peña ,&nbsp;D. García Hernández ,&nbsp;G.H. Portilla Quatrociocchi ,&nbsp;M. Jiménez Alonso ,&nbsp;M.C. Menchaca Echevarria","doi":"10.1016/j.remn.2024.500064","DOIUrl":"10.1016/j.remn.2024.500064","url":null,"abstract":"<div><h3>Objective</h3><div>Describe our experience in treatment with Phosphorus-32 (³²P) for refractory Philadelphia negative chronic myeloproliferative syndromes or with side effects to the usual treatment, its complications and risk of leukemic transformation.</div></div><div><h3>Material and methods</h3><div>Retrospective descriptive study including 17 patients with a diagnosis of Philadelphia-negative chronic myeloproliferative syndrome treated with ³²P in our hospital from January 1985 to March 2017. Indications, response to treatment, as well as early and late complications have been analyzed.</div></div><div><h3>Results</h3><div>Of the 17 patients treated with ³²P (11 men, 6 women; mean age 79.8 years), 6 patients had polycythemia vera and 11 essential thrombocytosis. A single dose was administered in 9 of the subjects, the rest required 2 or more doses due to inadequate hematological response and/or relapse. The total dose range of ³²P administered was 116-951<!--> <!-->MBq (median: 236<!--> <!-->MBq). In 14 patients treated with ³²P, complete or partial response was achieved in hematimetry. In 11 patients, the response was complete, established as a platelet count<!--> <!-->&lt;<!--> <!-->400.000/mm³ in those diagnosed with essential thrombocythemia and a hematocrit<!--> <!-->&lt;<!--> <!-->45% in cases of polycythemia vera. The median follow-up of patients from the date of the first treatment of ³²P until study completion or death was 37 months (range: 5-230 months). Regarding early complications, 2 cases of anemia requiring blood transfusion were observed, and one case of mild thrombocytopenia. No leukemic transformation was identified.</div></div><div><h3>Conclusions</h3><div>In our experience, treatment with ³²P has been a useful therapeutic option in Philadelphia-negative chronic myeloproliferative syndromes in elderly patients who showed poor tolerance and/or resistance to first-line treatment. No leukemic transformation was identified.</div></div>","PeriodicalId":48986,"journal":{"name":"Revista Espanola De Medicina Nuclear E Imagen Molecular","volume":"44 1","pages":"Article 500064"},"PeriodicalIF":1.6,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143105221","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Correlación entre respuesta metabólica determinada con [18F]FDG PET/TC y respuesta histológica tras tratamiento neoadyuvante y cirugía en pacientes con cáncer de esófago","authors":"J.R. Infante ,&nbsp;J. Quirós ,&nbsp;R. Barco ,&nbsp;C. Bejarano ,&nbsp;E. Agudo ,&nbsp;J. Fernández ,&nbsp;A. Baena ,&nbsp;A. Utrera ,&nbsp;A. Martínez ,&nbsp;C. Durán ,&nbsp;J. Serrano","doi":"10.1016/j.remn.2024.500088","DOIUrl":"10.1016/j.remn.2024.500088","url":null,"abstract":"<div><h3>Aim</h3><div>To assess the correlation between the result of the PET/CT study with [¹⁸F]FDG and the histological outcome in patients with esophageal cancer undergoing chemoradiotherapy and subsequent surgery.</div></div><div><h3>Material and methods</h3><div>41 patients (35 men) diagnosed with esophageal cancer during a 10-year interval were retrospectively evaluated. PERCIST criteria and SULpeak (ΔSULpeak) variation between pre- and post-treatment PET/CT studies were used. After neoadjuvant treatment and subsequent surgery, histological response and patient survival were determined, correlating the findings with the result of the metabolic study. Different parameters related to patient and tumors lesion characteristics were compared with respect to histologic response. ROC curves and the Kaplan-Meier method were applied for the analysis of prognostic factors and survival curves.</div></div><div><h3>Results</h3><div>The mean follow-up was 34.9 months, with 21 relapses-progressions and 25 deaths. Significant differences were demonstrated between histologic responses regarding PERCIST criteria and ΔSULpeak. Both showed adequate sensitivity and moderate specificity in relation to their histological correlation. No significant differences were found with respect to other parameters studied. Survival analysis showed significantly different progression-free survival curves for the ΔSULpeak and histologic outcome.</div></div><div><h3>Conclusion</h3><div>PERCIST criteria and ΔSULpeak differentiated between patients with and without histological response. ΔSULpeak and histological results proved to be prognostic factors. The results could help to personalize treatment and, together with other determinations, allow an active surveillance approach could be contemplated.</div></div>","PeriodicalId":48986,"journal":{"name":"Revista Espanola De Medicina Nuclear E Imagen Molecular","volume":"44 3","pages":"Article 500088"},"PeriodicalIF":1.6,"publicationDate":"2024-12-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143869300","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Papel del [99mTc]Tc-DPD gated-SPECT-TC en la evaluación de los patrones de captación miocárdica de la amiloidosis por transtiretina (AC-TTR)","authors":"F. Sebastián Palacid ,&nbsp;N. Álvarez Mena ,&nbsp;M. García Aragón ,&nbsp;R.d.C. Zambrano Infantino ,&nbsp;B.M. Jaramillo López ,&nbsp;J. Gómez Hidalgo ,&nbsp;B. Pérez López ,&nbsp;M.P. Redondo del Río ,&nbsp;R. Ruano Pérez","doi":"10.1016/j.remn.2024.500081","DOIUrl":"10.1016/j.remn.2024.500081","url":null,"abstract":"<div><h3>Purpose</h3><div>To evaluate the feasibility of identifying various distribution patterns of [^99mTc]Tc-DPD in patients with cardiac transthyretin amyloidosis using gated SPECT-CT.</div></div><div><h3>Materials and methods</h3><div>Gated SPECT-CT was performed in patients with a positive scintigraphy result for cardiac amyloidosis due to transthyretin (TTR-CA). Patients were categorized into several groups based on sex, degree of radiopharmaceutical uptake according to the Perugini's visual scale and ventricular ejection fraction (LVEF). Cardiac polar maps were obtained using Emory Cardiac Toolbox™ software and scored by segments according to radiopharmaceutical uptake on a scale from 0 (no uptake) to 4 (very high uptake intensity). The Mann-Whitney U and Pearson's Chi-square statistical tests were employed to identify significant differences in distribution patterns according to the different variables under study.</div></div><div><h3>Results</h3><div>A total of 65 patients were evaluated. The gender variable determined the main statistically significant differences, highlighting distinct distribution patterns of the radiopharmaceutical at the cardiac level: while women showed lower accumulation of [^99mTc]Tc-DPD in the middle anterior (<em>P</em> <!-->=<!--> <!-->0.035) and basal anterior (<em>P</em> <!-->=<!--> <!-->0.001) segments, whereas men demonstrated higher accumulation in the basal anteroseptal (<em>P</em> <!-->=<!--> <!-->0.009) and basal inferoseptal (<em>P</em> <!-->=<!--> <!-->0.009) segments, and lower scores in the lateroapical segment (<em>P</em> <!-->=<!--> <!-->0.039).</div></div><div><h3>Conclusions</h3><div>Gated SPECT-CT is an essential tool for assessing the distribution pattern of [^99mTc]Tc-DPD of patients with TTR-CA, offering valuable insights into the pathophysiology of the disease.</div></div>","PeriodicalId":48986,"journal":{"name":"Revista Espanola De Medicina Nuclear E Imagen Molecular","volume":"44 3","pages":"Article 500081"},"PeriodicalIF":1.6,"publicationDate":"2024-12-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143869299","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Terapia de ablación con yodo radiactivo de baja dosis (1,11 GBq) para el cáncer de tiroides diferenciado en el oeste de Turquía","authors":"B. Karaşah Erkek ,&nbsp;H. Sarıyıldız Gümüşgöz ,&nbsp;A. Oral ,&nbsp;B. Yazıcı ,&nbsp;A. Akgün","doi":"10.1016/j.remn.2024.500055","DOIUrl":"10.1016/j.remn.2024.500055","url":null,"abstract":"<div><h3>Objective</h3><div>Ablation therapy is employed in low-risk differentiated thyroid cancer (DTC) cases to facilitate patient monitoring by reducing thyroglobulin (Tg) levels to measurable levels below after surgery by eliminating residual thyroid tissue. However, there is still uncertainty about the minimum activity dose required for effective ablation. Opting for low-dose [¹³¹I]NaI for ablation offers several advantages for both patients and healthcare services. Particularly in this tumor group with a high life expectancy (approximately 90-95% at 10<!--> <!-->years) [¹³¹I]NaI treatment should not pose a risk to the patient's post-treatment life and should not compromise their quality of life. However, there is a need for a well-defined identification of factors predicting successful ablation.</div></div><div><h3>Methods</h3><div>Clinical data, laboratory findings, and imaging tests of 287 patients with low-dose 1110<!--> <!-->MBq (30<!--> <!-->mCi) [¹³¹I]NaI ablation therapy for DTC were retrospectively reviewed. Post-ablation imaging and laboratory findings categorized ablation success/failure. The successful ablation group was determined according to the excellent response criteria outlined in ATA criteria. Relationships between clinical, pathological findings, biochemical common variables, and treatment failure were analyzed.</div></div><div><h3>Results</h3><div>An excellent response was achieved in 77% of the entire group according to ATA criteria post-ablation. Male gender and high Tg levels on the day of ablation (Tg cut-off: 10<!--> <!-->ng/ml and 5.35<!--> <!-->ng/ml) were associated with unsuccessful ablation.</div></div><div><h3>Conclusions</h3><div>Our results indicate that a 1110 MBq (30<!--> <!-->mCi) ablation dose is sufficient to achieve an excellent response in most low-risk DTC cases 6-12<!--> <!--> onths later. When selecting the dose for ablation, besides the histological markers mentioned in guidelines and age, we observed that stimulated Tg values and gender may be important in predicting ablation success.</div></div>","PeriodicalId":48986,"journal":{"name":"Revista Espanola De Medicina Nuclear E Imagen Molecular","volume":"43 6","pages":"Article 500055"},"PeriodicalIF":1.6,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142658156","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Evaluación del papel de la sarcopenia y de los parámetros de la PET/TC con [18F]FDG en el pronóstico del adenocarcinoma ductal de páncreas","authors":"H. Önner,&nbsp;M.N. Calderon Tobar,&nbsp;L. Perktaş,&nbsp;F. Yilmaz,&nbsp;G. Kara Gedik","doi":"10.1016/j.remn.2024.500046","DOIUrl":"10.1016/j.remn.2024.500046","url":null,"abstract":"<div><div>This study investigates the relationship between ¹⁸F-fluorodeoxyglucose ([¹⁸F]FDG) positron emission tomography/computed tomography (PET/CT) metabolic parameters, clinicopathological characteristics, and sarcopenia in patients with pancreatic ductal adenocarcinoma (PDAC) and evaluates their prognostic roles.</div></div><div><h3>Material and methods</h3><div>The primary tumor's maximum standard uptake (SUVmax), metabolic tumor volume (MTV), and total lesion glycolysis (TLG) values, as well as clinicopathological factors, were evaluated retrospectively. Computed tomography (CT) was used to assess the skeletal muscle index (SMI). Sarcopenia was defined based on SMI calculated at the third lumbar vertebra (L3). SMI cut-off values for sarcopenia were accepted as 44.77<!--> <!-->cm²/m² for men and 32.50<!--> <!-->cm²/m² for women. The primary endpoint was the overall survival (OS). OS data were analyzed by the Kaplan-Meier method and compared using the log-rank test. To identify predictive factors for sarcopenia, multivariable logistic regression was used following univariable logistic regression. Cox proportional hazards regression analyses were used to find predictors of OS.</div></div><div><h3>Results</h3><div>Of the 86 patients included in the study, 37 (43%) were diagnosed with sarcopenia. Compared with non-sarcopenic patients, sarcopenia was observed in older patients (<em>P</em> <!-->=<!--> <!-->.028) and patients with lower body mass index (BMI) (<em>P</em> <!-->=<!--> <!-->.001). Age and BMI independently predicted sarcopenia. Univariate analysis identified sarcopenia, advanced stage, and higher primary tumor TLG as significant predictors of overall survival. Multivariate Cox regression analysis revealed that the advanced tumor stage (<em>P</em> <!-->=<!--> <!-->.017) and higher TLG (<em>P</em> <!-->=<!--> <!-->.042) independently predicted OS. The median OS was 9.4<!--> <!-->months in non-sarcopenic patients and 5.0<!--> <!-->months in sarcopenic patients (<em>P</em> <!-->=<!--> <!-->.021).</div></div><div><h3>Conclusion</h3><div>In this study cohort, advanced-stage disease and higher primary tumor TLG were identified as independent predictors of OS in patients with PDAC. Additionally, we emphasize the importance of incorporating [¹⁸F]FDG PET/CT-derived sarcopenia assessments into the prognostic evaluation and clinical management of PDAC patients. While sarcopenia was associated with shorter OS in univariate analysis, it was not an independent predictor in multivariate analysis.</div></div>","PeriodicalId":48986,"journal":{"name":"Revista Espanola De Medicina Nuclear E Imagen Molecular","volume":"43 6","pages":"Article 500046"},"PeriodicalIF":1.6,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142658247","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Asociación entre las imágenes SPECT/CT con 99mTc-PSMA y los niveles de antígeno prostático específico (PSA) y fosfatasa alcalina (ALP) después de la terapia endocrina en pacientes con cáncer de próstata y metástasis óseas","authors":"X. Ruan ,&nbsp;Y. Gao","doi":"10.1016/j.remn.2024.500054","DOIUrl":"10.1016/j.remn.2024.500054","url":null,"abstract":"<div><h3>Aim</h3><div>To investigate the association between positive lesions detected by 99mTc-PSMA SPECT/CT and blood levels of prostate-specific antigen (PSA) and alkaline phosphatase (ALP) in patients with prostate cancer (PCa) and bone metastasis undergoing endocrine therapy.</div></div><div><h3>Methods</h3><div>A retrospective analysis was performed on 43 patients diagnosed with PCa bone metastasis who underwent endocrine therapy. PSA, ALP, whole body bone imaging and 99mTc-PSMA SPECT/CT imaging were collected from all patients (Among them, 17 cases were re-examined 99mTc-PSMA SPECT/CT imaging). According to the results of the first 99mTc-PSMA SPECT/CT imaging for detecting bone metastasis, all cases were divided into two groups: positive group and negative group. The relationship between 99mTc-PSMA imaging and PSA and ALP was analyzed by ROC curve. Fisher exact probability method was used to examine the changes in imaging radioactivity uptake, PSA, and ALP levels in 17 patients after treatment, and <em>P</em> <!-->&lt;<!--> <!-->0.05 was statistically significant.</div></div><div><h3>Results</h3><div>All 43 patients had different degrees of radioactive concentrations on whole-body bone imaging. The first 99mTc-PSMA SPECT/CT imaging showed positive bone metastases in 31 cases and negative bone metastases in 12 cases. ROC curve analysis of PSA and ALP, AUC were 0.778 and 0.770, respectively. When PSA<!--> <!-->&gt;<!--> <!-->1.13<!--> <!-->ng/mL, 99mTc-PSMA SPECT/CT imaging diagnostic sensitivity was 93.55%, and specificity was 66.67%. When ALP was &gt;86U/L, the diagnostic sensitivity of 99mTc-PSMA SPECT/CT imaging was 64.52%, and the specificity was 83.33%. In 17 cases, the PSA level decreased in 7 and increased in 10. There were 10 cases of increased ALP and 7 cases of decreased ALP levels. In the second 99mTc-PSMA imaging lesion, there were 9 cases with decreased or no uptake, and 8 cases with increased uptake or number of lesions. The changes in 99mTc-PSMA uptake by Fisher's exact probability method were statistically significant (<em>P</em> <!-->&lt;<!--> <!-->0.05, <em>P</em> <!-->=<!--> <!-->0.006, and <em>P</em> <!-->=<!--> <!-->0.006, respectively), and ALP level was not statistically significant (<em>P</em> <!-->=<!--> <!-->0.563).</div></div><div><h3>Conclusion</h3><div>99mTc-PSMA SPECT/CT imaging can detect PCa bone metastases, which are related to PSA levels. When PSA<!--> <!-->&gt;<!--> <!-->1.13<!--> <!-->ng/mL, the sensitivity of diagnosis and detection of positive bone metastases is higher, and when ALP is &gt;86U/L, 99mTc-PSMA imaging has higher specificity.</div></div>","PeriodicalId":48986,"journal":{"name":"Revista Espanola De Medicina Nuclear E Imagen Molecular","volume":"43 6","pages":"Article 500054"},"PeriodicalIF":1.6,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142658155","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}